This study is looking at a drug called visugromab (also known as CTL-002) for people who have advanced cancer (like lung or bowel cancer) and are experiencing unintended weight loss, called cachexia. Researchers want to see if visugromab can help you gain weight and improve your appetite. They also want to understand if it helps you move more and what side effects you might experience. You would receive visugromab (in different doses) or a placebo (a substance with no drug) through an IV drip. The study aims to enroll 518 participants, and your body weight and appetite will be checked at 12 weeks to see how the treatment is working. You can join if you are 18 or older and have experienced weight loss and advanced cancer.

Study design

This is an interventional study comparing different doses of visugromab to a placebo. It plans to enroll 518 participants.

What's involved

You will visit the hospital or clinic once every 4 weeks to receive the study drug or placebo via an IV drip, and for checkups and tests.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for measuring changes in body weight and appetite are at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.